Breaking Update
New Clinical Trial Explores Blood Draws as Alternative to Bone Marrow Biopsy
New clinical trial explores blood draws as alternative to bone marrow biopsy. Israeli, American, and global partners aim to revolutionize hematology
Jerusalem, 10 September, 2025 (TPS-IL) — Israeli biotech firm CLISEQ Ltd., American life sciences company 10x Genomics, and Israel’s Weizmann Institute of Science have launched the PERIBLOOD trial, a global clinical study exploring single cell RNA sequencing from blood as a non-invasive alternative to bone marrow aspiration in diagnosing blood disorders. The three-year study, led by the Weizmann Institute, aims to enroll more than 1,500 participants across sites in North America, Europe, Asia, Latin America, and Israel.
By comparing single cell profiles from blood and bone marrow, researchers hope to validate a simpler, less painful diagnostic method for conditions such as Myelodysplastic Syndromes (MDS). Findings could transform hematology diagnostics and improve patient care worldwide.
